Exelixis (NASDAQ:EXEL) : The consensus price target for Exelixis (NASDAQ:EXEL) is $7.67 for the short term with a standard deviation of $2.52. The most optimist securities analyst among the 3 who monitor the stock believes that the stock can reach $10, however, the pessimist price target for the company is $5.
Exelixis, Inc. has dropped 0.51% in the last five trading days, however, the shares have posted positive gains of 20.52% in the last 4 weeks. Exelixis, Inc. is up 92.84% in the last 3-month period. Year-to-Date the stock performance stands at 38.48%. Also, Equity analysts at the Brokerage firm Stifel Nicolaus upgrades its rating on Exelixis (NASDAQ:EXEL). The rating major has initiated the coverage with buy rating on the shares. Earlier, the shares were rated a Hold by the brokerage firm. The rating by the firm was issued on April 4, 2016.
Exelixis (NASDAQ:EXEL) has an average broker rating of 1.4, which is interpreted as a Strong Buy, as rated by 5 equity analysts. Nonetheless, 4 analysts are positive on the stocks future and they recommend a Strong Buy on the stock. Nevertheless, the majority of 1 analysts consider that the stock is a Hold with neither a large upside nor a downside. Ranking by Zacks Investment Research for Coach Inc is 3, which is also a Hold.
Exelixis (NASDAQ:EXEL): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $7.79 and $7.71 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $7.87. The buying momentum continued till the end and the stock did not give up its gains. It closed at $7.81, notching a gain of 0.13% for the day. The total traded volume was 14,507,084 . The stock had closed at $7.80 on the previous day.
In an insider trading activity, Willsey Lance, director of Exelixis, Inc., executed a transaction worth $297,600 on May 9, 2016. A total of 60,000 shares were purchased at an average price of $4.96. The Insider information was divulged by the Securities and Exchange Commission in a Form 4 filing. The information is based on open market trades at the market prices.Option exercises are not covered.
Exelixis Inc. is a biopharmaceutical company. The Company is engaged in developing small molecule therapies for the treatment of cancer. The Company is focusing on resources development and commercialization of COMETRIQ (cabozantinib) for the treatment of progressive, metastatic medullary thyroid cancer (MTC) in the United States. The Companys other programs include metastatic renal cell carcinoma (mRCC), a phase III trial comparing cabozantinib to everolimus in patients with mRCC who have experienced disease progression following treatment with at least one prior VEGFR TKI; CELESTIAL, a phase III trial comparing cabozantinib with placebo in patients with advanced hepatocellular cancer (HCC) who have previously been treated with sorafenib; NSCLC (non-small cell lung cancer); mCRPC (metastatic castration-resistant prostate cancer) and XL888, a small molecule oral inhibitor of Heat Shock Protein 90 (HSP90).